Skip to search.
 TSX Down0.74% TSX Ventures 0.00%

Alnylam Pharmaceuticals, Inc. (ALNY)

-NasdaqGS

28.06 Up 0.22(0.79%) 4:00PM EDT|After Hours : 28.06 0.00 (0.00%) 4:37PM EDT

Add to Portfolio
Income StatementGet Income Statement for:
View: Annual Data | Quarterly DataAll numbers in thousands
Period Ending2012-12-302011-12-302010-12-30
Total Revenue 66,725   82,757   100,041  
Cost of Revenue -   -   -  
Gross Profit 66,725   82,757   100,041  
Operating Expenses
Research Development86,569  99,295  106,384  
Selling General and Administrative44,612  38,280  37,727  
Non Recurring65,000   -   -  
Others -   -   -  
Total Operating Expenses -   -   -  
Operating Income or Loss (129,456) (54,818) (44,070)
Income from Continuing Operations
Total Other Income/Expenses Net17,392  674  8,708  
Earnings Before Interest And Taxes(116,586)(57,649)(43,001)
Interest Expense -   -   -  
Income Before Tax(116,586)(57,649)(43,001)
Income Tax Expense(10,572) -  514  
Minority Interest -   -   -  
Net Income From Continuing Ops(110,536)(61,154)(51,154)
Non-recurring Events
Discontinued Operations -   -   -  
Extraordinary Items -   -   -  
Effect Of Accounting Changes -   -   -  
Other Items -   -   -  
Net Income (106,014) (57,649) (43,515)
Preferred Stock And Other Adjustments -   -   -  
Net Income Applicable To Common Shares (106,014) (57,649) (43,515)

Sign Up for a Free Trial to EDGAR Online Premium!
Get the critical business and financial information you need for more than 15,000 U.S. public companies.
Sign Up Now - Learn More

Currency in USD.